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Abstract
Malignant pleural mesothelioma (MPM) is a rare and highly drug resistant tumor arising from the mesothelial surfaces
of the lung pleura. The standard method to confirm MPM is the tedious, time-consuming cytological examination of
cancer biopsy. Biomarkers that are detectable in pleural effusion or patient serum are reasonable options to provide a
faster and noninvasive diagnostic approach. As yet, the current biomarkers for MPM lack specificity and sensitivity to
discriminate this neoplasm from other lung tumors. CD44, a multifunctional surface receptor has been implicated in
tumor progression in different cancers including MPM. The interaction of CD44 with its ligand, hyaluronan (HA) has
demonstrated an important role in modulating cell proliferation and invasiveness in MPM. In particular, the high
expression levels of these molecules have shown diagnostic relevance in MPM. This review will summarize the
biology and diagnostic implication of CD44 and HA as well as the interaction of both molecules in MPM that will
demonstrate their potential as biomarkers. Augmentation of the current markers in MPM may lead to an earlier
diagnosis and management of this disease.
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Background
MPM is an aggressive, and locally invasive tumor eman-
ating from the mesothelial cells of the pleura mainly due
to chronic exposure to asbestos fibers [1–3]. Although it
is well accepted that asbestos is the major causative
agent of MPM, the number of cases involving persons
with less asbestos exposure is also increasing [4]. The
diagnosis of MPM is complex because of its composite
epithelial/mesenchymal patterns, its phenotypic variabil-
ity from patient to patient, and its property to mimic
other cancers particularly, adenocarcinoma or benign
processes [5]. Histologically, MPM is divided into
epitheloid, sarcomatoid and biphasic subtypes, which
has an impact on diagnosis, treatment and prognosis of
the disease. The epitheloid is the most common and
least aggressive representing 50–70% of all MPM cases.
The sarcomatoid, a less prevalent subtype is the most
aggressive form and by far difficult to manage. The
biphasic, a combination of both epitheloid and
sarcomatoid comprises 20–35% of all MPM cases [6, 7].
MPM is highly tolerant to all standard treatments that
include the first-line chemotherapy consisting of
cisplatin and pemetrexed, surgery and radiation [1].
Response rate to standard chemotherapy is 20–40% with
a median survival time of less than 12 months [6, 8].
Prognosis remains poor because of the difficulties of
early diagnosis, hence, application of biomakers with
high sensitivity particularly for the early stage of the
disease remains a continuing task [9, 10].
The National Cancer Institute defines a biomarker as a
biological molecule found in the blood, body fluids or
tissues representing a sign of a normal or abnormal
process, or of a condition or disease. Biomarkers include
proteins (e.g. enzyme or receptor), nucleic acids (e.g.
micro RNA), antibodies and peptides and, thus, can be
easily obtained noninvasively and serially [11], and neither
require biopsy or special imaging for evaluation [12].
One of the established tumor biomarkers is the cluster
of differentiation 44 (CD44), an adhesion/homing
molecule and the major receptor for HA [13–15]. As a
multifunctional cell surface receptor, CD44 has been
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associated in the development of many neoplasms
because of its modulating ability in cancer progression
such as conveying cell adhesion and cell migration that
aids the expansion of tumors [16–18]. CD44 has also
been dubbed as a putative cancer stem cell (CSC) in
lung cancers and MPM because of its significant influ-
ence on disease progression and negative treatment
outcome [19–25]. These attributes render CD44 as a
biomarker in screening, differential diagnosis and predic-
tion of response to therapy [26]. HA, the most common
ligand of CD44 [19] is a glycosaminoglycan (GAG),
which is widely distributed within the extracellular
matrix. In this compartment, HA regulates different
cellular activities such as cell migration, growth and
differentiation and cell adhesion [27–30]. High levels of
HA in pleural effusions of MPM patients have shown evi-
dence of its diagnostic value in MPM sustaining the idea
of being a predictive biomarker in this tumor [31–37].
Herein, we will describe the biology of CD44 and HA, and
summarize their diagnostic performance in MPM. It will
also discuss the inaccuracy of the conventional biomarkers
in pleural fluids/serum for MPM as well as the rationale
why CD44 and HA may serve as diagnostic biomarkers
that may add to an earlier diagnosis and commencement
of appropriate therapies in this disease.
CD44 molecule
CD44 is a cell surface adhesion molecule involved in
cell-cell and cell-matrix interactions [16, 38]. The inter-
action of CD44 with its ligand and associated molecules
regulate cell adhesiveness, cell motility, matrix degrad-
ation, cell proliferation and survival that potentiate its
crucial role in carcinogenesis [17, 18]. CD44, the major
receptor for the hyaluronan (previously named hyalur-
onic acid, HA) is endogeneously expressed at low levels
in different types of normal tissues that necessitates
activation before binding to HA [39, 40]. Variant
isoforms of CD44 specially, CD44 v6-v10 are overex-
pressed in both human and animal neoplasms indicating
its implication in cancer progression, whereas its re-
moval is associated with inhibition of tumor growth
[41–44]. Inhibitors such as exemestane, trametinib and
statin exert profound antiproliferative effects on meso-
thelioma growth either by a direct downregulation of
CD44 [45] or the suppression of CD44 and its associated
signaling pathways [46, 47] attesting the critical role of
CD44 in modulating tumor growth in MPM.
The CD44 structure on normal cells is different from
that on tumor cells because under various physiological
and pathological conditions, the local environmental
pressure alters splicing and post-translational modifications
to produce various types of CD44 molecules with enhanced
HA binding that triggers increased tumorigenicity [13, 16,
48–51]. CD44 can be cleaved at the membrane-proximal
region of the ectodomain by MT1-MMP (membrane
type 1 matrix metalloproteinase), which is thought to
play an essential role in CD44-mediated tumor cell migra-
tion alongside with extracellular matrix components [52–
54]. Although all CD44 isoforms are endowed with HA
recognition sites, not all cells bearing CD44 bind the HA
ligand constitutively. In addition to HA, CD44 interacts
with different ECM proteins such as fibronectin, colla-
gens, growth factors, cytokines, chemokines, matrix me-
talloproteinases and osteopontin [16].
Twenty exons are involved in the genomic organization
of CD44. The first five and the last five exons are constant
whereas the ten exons located between these regions are
subjected to alternative splicing from which the variable
regions emanate (Fig. 1a). The smallest molecule (85–
95 kDa) without the variable region is the standard CD44
(CD44s) (Fig. 1b). As this is found mainly on cells of lym-
phohematopoietic origin, CD44s is also known as
hematopoietic CD44 (CD44H). After immunological acti-
vation, T lymphocytes and other leukocytes transiently up-
regulate CD44 isoforms expressing variant exons
designated as CD44v. A CD44 isoform containing the last
exon products of the variable region, CD44v8-10 is also
known as epithelial CD44 (CD44E) and is preferentially
expressed on epithelial cells [50]. CD44v6 (CD44 variant
exon 6) is the major CD44 isoform that regulates tumor
invasion, progression and metastasis [18, 55] (Fig. 1c).
Several MPM cell lines are positive for CD44v9 (vari-
able exon 9) including the CD44v8-10, the former being
statistically associated with NF2 (neurofibromatosis
type 2), a common feature of MPM [56]. The protein
structure of CD44 consists of an N-terminal HA-
binding link-homology motif, stem region, transmem-
brane domain and short C-terminal cytoplasmic region
(Fig. 1d). CD44 binds to its major ligand, HA via the N-
terminal HA- binding link-homology motif. The C-
terminal cytoplasmic region has a major role in eliciting
the essential functions of CD44 in the regulation of
intracellular signal transduction through binding to dif-
ferent molecules such as the cytoskeleton components,
kinases and activators of small Rho GTPases [57, 58].
CD44 ligand, hyaluronan
Balazs et al. [59] introduced the term “hyaluronan” in
1986 to conform with the international nomenclature
of polysaccharides to include the different forms this
molecule can take such as the acid form, hyaluronic,
and the salt form, sodium hyaluronate. [60]. HA is a
non-sulfated, linear GAG consisting of repeating disac-
charides of (ß, 1–4)-glucoronic acid (GlcUA) and (ß, 1–
3)-N-acetyl glucosamine (GlcNAc). HA is synthesized
at the cell plasma membrane by specific hyaluronan
synthases (HAS); HAS-1, HAS-2 and HAS-3 and is dir-
ectly released into the extracellular matrix [14, 30]. At
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the cellular level, HA plays essential roles in modulation
of tissue architecture, cell motility, cell proliferation and is
a prominent component of the microenvironment in most
malignant tumors [14, 42]. The diverse functions of HA
within the extracellular matrix is a result of the different
HA-binding receptors such as CD44, RHAMM (receptor
for HA-mediated motility), other receptors bearing HA-
binding motifs such as the transmembrane protein layilin,
HARE (HA receptor for endocytosis), LYVE-1 (lymphatic
vessel endocytic receptor), intracellular HA-binding
proteins including CD37, RHAMM/IHABP (intracellu-
lar HA-binding protein), P-32 and IHABP4 [28, 60].
Upregulated HA production is supposed to produce less
dense matrix, hence, providing the cell a suitable platform
for increased cell motility and invasion property [61].
Because HA not only provides a cellular support and
hydrophilic matrix but also facilitates cell-cell adhesion,
cell migration, growth and differentiation, these properties
bestow HA as a suitable candidate in modulating patho-
logical processes such as cancer [29, 62]. Elevated levels of
HA have been detected in different types of human cancer
and its accumulation within the tumor stroma has been
associated with poor prognosis and survival in cancer
patient [63]. In liver fibrosis, increasing levels of serum
HA have been measured during the progression of the
disease [64–66].
In tumors, HA binding to CD44 evokes an interaction
of CD44 with signaling receptors such as the epidermal
growth factor receptor-2 (ErbB2), epidermal growth
factor receptor (EGFR) and transforming growth factor
beta receptor type 1 (TGFßR1) that consequently alters
the physiological effects of these receptors [67–69]. It
can also interact and consequently modify the activity
of nonreceptor kinases of the Src family or Ras family
GTPases, and with switch molecules such as RhoA,
Rac1 and Ras via adaptor proteins that generate intracellu-
lar signaling circuits [14, 15, 67, 68, 70, 71]. In such a way,
CD44/HA binding modifies the activity of different down-
stream signaling cascades, in particular, the MAP kinase
and PI3/Akt pathways and consequently convey tumor
cell proliferation, cell survival, cell motility and invasive-
ness and chemoresistance [14, 72] (Fig. 2).
CD44/HA interactions in MPM
CD44 in cancer cells interacts with hyaluronan-rich
microenvironments modifying cell signaling pathways
that trigger the ability of malignant cells to migrate, to
invade basement membranes and to lodge at distant
Fig. 1 Genomic and protein structures of CD44. a The human CD44 gene consists of 20 exons. Those encoding for N-terminal, transmembrane
and cytoplasmic domains as well as the exon numbers are shown. Alternative splicing of variable exons, v1-v10 generates CD44 variant isoforms.
b The standard CD44 (CD44s) consists of exons 1–5, 16–20. c The variant form, CD44v6 contains the standard exons 1–5, 16–20 and variant exon
11 (v6). d CD44 is a single-pass transmembrane glycoprotein consisting of four functional domains: N-terminal domain, stem region, transmembrane
domain and the intracellular cytoplasmic domain. N-terminal domain, the site for HA binding is bound together by three cysteine disulfide cross-links.
Alternative splicing occurs at the stem region generating the variant form. The transmembrane domain anchors the molecule in the
cytoplasmic membrane, whereas the cytoplasmic region conveys essential functions of CD44. v, variant exon, UTR, untranslated region
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sites of the tumor [14, 70, 73]. That CD44/HA binding
mediates several tumor cell-specific activities and pro-
gression indicates that CD44/HA interactions play a
pivotal role in cancer development [67, 71]. In MPM,
the presence of HA and its receptor, CD44 have been
shown to facilitate neoplastic cell motility and invasion
linking CD44/HA interactions in tumor progression.
Li and Heldin [27] provided evidence that the overex-
pression of hyaluronan synthase 2 (HAS2) in a nonhya-
luronan producing MPM cell line, Mero-25, changed the
histological type of Mero-25 from less aggressive epithe-
loid to a more aggressive fibroblastic phenotype. These
authors further observed that HAS2-transfected cells
demonstrated a two-fold increase in the expression of
the HA receptor, CD44 accompanied by increased cell
motility, thus, disclosing the critical role of HA in the
dissemination of mesothelioma cells in adjacent nontu-
mor tissues. In a separate study, HA/CD44 interactions
in the 2 MPM cell lines ACC-MESO-1 and K921MSO,
exhibited a crucial role in driving cell proliferation and
invasiveness. These MPM cell lines, which express high
quantities of CD44 demonstrated enhanced cell prolifer-
ation and upregulated invasion capacity after HA treat-
ments, in vitro. Notably, it was found that silencing of
CD44 significantly abrogated the HA-mediated cellular
effects in the 2 MPM cell lines indicating the essential
role of CD44/HA binding in modulating migration and
proliferation of mesothelioma cells [74].
A comparative analysis between the low molecular weight
hyaluronan (LMWHA) and high molecular weight hya-
luronan (HMWHA) has been performed to assess their
capacity in mediating cell proliferation and migration
on 4 MPM cell lines, expressing CD44. This study made
evident that the MPM cell line expressing the highest level
of CD44 was induced by LMWHA, which resulted to an
increased cell proliferation and haptotaxic migration. In this
work, CD44 neutralization profoundly reduced LMWHA
binding to MMC (malignant mesothelima cells) illustrating
that the interaction between CD44 and HA components
transmit regulatory signals conferring locomotion and
proliferation of MMC and, thus, show their participa-
tion in the expansion of tumor [7].
A mechanistic CD44/HA association in MPM has been
observed by Asplund and Heldin [75]. These authors found
HA-binding sites on the cell surface of three tumor-derived
MPM cell lines, which were absent in normal mesothelial
cells. The HA receptors appeared to be related to CD44
because the human CD44 monoclonal antibody, Hermes-1,
which prevented the binding of HA to CD44 suppressed
the major part of the HA binding mechanism. However, no
strict correlation was recorded between the HA binding
activity on the tested cells, and the levels of CD44
molecules on their cell surfaces indicating that only a
fraction of the HA was bound to the CD44, and that
other HA binding proteins may also exist. This study
also revealed that the pleural fluids from MPM patients
were capable of stimulating HA synthesis in primary
mesothelial cultures expressing functionally active HA
receptors, CD44.
Osteopontin (OPN), a secreted tumor-associated, non-
collagenous phosphoprotein is an extracellular matrix
component and a cytokine through binding to its recep-
tors integrin and CD44 [76, 77]. An important role of
OPN in MPM has been reported such as the modulation
of multidrug resistance via osteopontin-dependent regu-
lation of HA-CD44 interaction. Tajima and coworkers
[78] presented evidence that the insertion of OPN gene
in stable transfected ACC-MESO-1/OPN cell line upreg-
ulated the multidrug resistance through the mechanism
of enhanced HA binding. Notably, the inhibition of HA-
CD44 interaction abrogated multidrug resistance in the
ACC-MESO-1/OPN sustaining an important role of
Fig. 2 CD44/HA interaction in tumor. CD44/HA binding in the
malignant setting elicits an interaction of CD44 with ErbB2, EGFR
and TGFßR1 that alter the physiological effects of these receptors. It
transmits signals through the cytoplasmic domain after binding with
diverse cytoskeletal proteins such as actin-cytoskeleton adaptor
protein, ankyrin, ezrin-redixin-moesin (ERM) proteins, intracellular
signaling components including the Rho family GTPases, Src kinases and
associated molecules. To a great extent, MAP kinase and PI3 kinase/AKT
signaling mediate cell proliferation, cell survival, cell motility and invasion
as well chemoresistance [14]. ErbB2, epidermal growth factor receptor-2,
EGFR, epidermal growth factor receptor, TGFßR1, transforming growth
factor beta receptor 1, GTPases, family of hydrolase enzymes that bind
and hydrolyse guanosine triphosphate (GTP)
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HA-CD44 association in the regulation of drug tolerance
and, thus, demonstrate that OPN is essentially impli-
cated in conveying multidrug resistance by enhancing
CD44 binding to HA.
Diagnostic relevance of CD44 in MPM
As in the case of other biomarkers, the utility of CD44
as a diagnostic and/or prognostic marker was originally
suggested because of its altered overexpression in human
tumor tissues as compared with the nontumor or corre-
sponding normal tissues. An early study of Penno et al.
[79] has demonstrated that CD44 can be detected immu-
nohistochemically in MPM tissues illustrating the pres-
ence of neoplastic cells. In this project, using a CD44
monoclonal antibody (H4C4), 92% of the MPM samples
were found to contain 50–100% CD44 relative to the total
number of cells. It was further noted that CD44 expres-
sion was related to the histological type of MPM, with the
highest levels observed in the epitheloid subtype and the
least in sarcomatoid. These authors also elucidated that
increased CD44 levels modulates the association with HA,
a major component of the pleural fluid.
Because MPM is more aggressive than pulmonary
adenocarcinoma (ADC), Attanoos and coworkers [80]
tested the diagnostic potential of CD44 to discriminate
the two neoplasms by immunohistochemistry (IHC) in
reactive mesothelium, pleural mesothelioma and pulmonary
ADC. A strong immunoreactivity of CD44H (CD44s) was
detected in all 20 biopsies of reactive mesothelium and in
75% of MPM specimens as compared to only 15% in
pulmonary ADC, thus, proposing the utility of CD44H
as a positive mesothelial marker alongside with established
immunohistochemical indicators to differentiate ADC
from MPM. CD44 localization in addition to HA by IHC
has also been reported to discriminate MPM from ADC
[81]. Membranous staining for CD44s was assessed posi-
tive in 100% of mesothelial hyperplasia, 86% of malignant
mesothelioma and 8% of lung ADCs indicating that
CD44s is a reliable marker to distinguish MPM from
ADC. In yet another study, low CD44 expression was
detected in MPM (57.7%) and in mesothelial hyperplasia
(11.5%) using immunohistochemical analysis. Despite of
the low expression of CD44 in the malignant samples, it
was suggested that the mere presence of CD44 confirmed
its potential as a positive mesothelial marker in the differ-
ential diagnosis of pleural neoplastic proliferation [82].
Using CD44, hyaluronan and HASs as putative markers
for differentiating MPM from adenocarcinomas (ADCs),
Törrönen et al. [83] recently found a surprisingly low
CD44 positivity of stromal cells in ADCs as compared
to mesotheliomas (MPMs). This report is unanticipated
in the sense that, most results have accounted for an
increased CD44 levels in MPM in contrast to those in
ADCs [79, 80].
Porcel and colleagues [84] also compared the diagnostic
utility of the concentrations of CD44v6 and CD44s in
pleural fluids as biomarkers for distinguishing MPM from
nonmesothelioma tumors. The CD44v6/CD44s ratio
obtained from the concentration levels between MPM
and other pleural malignancies has been proven as a re-
liable diagnostic tool for the differential diagnosis of
malignant pleural effusions such that those with a high
probability of being metastatic and, hence, preventing
the need of an invasive thoracoscopy. An overview of
the diagnostic relevance of CD44 in MPM is shown in
Table 1.
Diagnostic value of HA in MPM
One of the earliest pathological reports on HA was its
isolation in 1939 from the pleural fluid of a patient with
a malignant tumor of the pleural and peritoneum, which
demonstrated that neoplastic cells secrete HA [85]. This
was followed by a consensus that the high concentration
of HA in the pleural effusions or ascites of MPM
patients is a standard finding [37, 86, 87] or is associated
with MPM [83]. Indeed about 70% of MPM patients exhibit
high levels of HA in pleural effusions or serum [88] in
which a direct correlation has been found between the up-
regulated hyaluronan levels in the circulation and tumor
damage in HA-producing mesotheliomas [34, 35, 88].
One parameter by which MPM affirms its mesenchymal
origin is by the formation of HA, making it as one of the
most important criteria in distinguishing between MPM
and metastatic ADC [80, 87, 89]. In fact, tumor-secreted
HA in the pleural fluid has been suggested as a means of
identifying MPMs [31, 33, 81, 86, 90–93]. In this context,
Waxler and coworkers [94] developed a method for
isolating HA and other GAGs from tumor tissues and
observed that MPMs contained only or almost entirely
HA, whereas carcinomas and sarcomas consisted of a
mixture of HA and other GAGs. Based on this, these
authors concluded HA as the sole or major GAG to
confirm a diagnosis of MPM. Another study suggested
that increased total GAG aids in the differential diag-
nosis between MPM and diffuse ADC [95] and is a
basic finding in addition to the elevated levels of HA
and chondroitin sulfate in MPM [96]. Welker et al.
[97] further recommended that the combination of HA
and cytology may even improve the diagnosis of MPM.
An earlier report has found that HA values of > 0.25 μg/ml
in pleural effusions indicates the presence of MPM [86].
Using a higher cut-off level of 100 μg/ml for HA, Atagi et al.
[92] as well as Petterson and colleagues [33] reported that
such a high concentration of HA in the pleural fluid
combined with a low concentration of carcinoembryonic
antigen (CEA) aid in the differential diagnosis for MPM.
As a single marker, HA values of >100 μg/ml has been
recommended as a diagnostic indicator for MPM [31].
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High serum levels of HA in MPM patients have been
measured in MPM patients in later and progressive
stages [34] denoting HA as a marker of a progressive
disease [35, 88]. An accumulation of high intracellular
HA, a feature that is not reported in ADC, could distin-
guish MPM from ADC according to Afify and coworkers
[81]. Their study revealed that all MPMs and 93% of the
benign mesothelial cells were positive for intracytoplas-
mic HA as compared with a 100% negativity in ADCs. In
contrast to this report, the group of Chiu [87] claimed that
HA is neither the sole nor the predominant GAG in most
MPMs. These authors found that quantitatively, MPMs ex-
hibited statistically higher amounts of HA than primary
lung ADCs but were not statistically different from soft tis-
sue sarcomas or primary ovarian serous neoplasms. Hence,
they suggested that high levels of HA support the diagnosis
of MPM when the alternative diagnosis is primary ADC of
the lung. Intriguingly, high levels of HA in pleural fluid
have been proposed not to be specific for MPM as it can
also occur in other malignant or benign diseases and a low
level does not exclude MPM [98].
Another aspect of importance is that the pleural fluids
from MPM patients exhibited profound HA-stimulatory
activity as compared with the nonmesothelioma fluids,
thus, demonstrating that HA-binding capacity may serve
as an additional marker in combination with other diag-
nostic tools to delineate between MPM and normal
mesothelial cells [99]. Table 2 shows an overview of the
diagnostic value of HA in MPM.
CD44, a putative cancer stem cell marker in MPM
MPM is a notoriously chemoresistant neoplasm which
led to the identification of a cancer stem cell subpopulation
with the presumption that these cells are crucial candidates
for conferring drug tolerance. The CSC model proposes
that these cells have the capacity for self-renewal,
re-initiation of tumor growth and innate resistance to
chemotherapy [23, 25, 26, 100]. CD44, principally,
CD44v isoforms are CSC markers that play essential
roles in the execution of the fundamental features of
CSCs [19, 26, 101, 102]. Hence, CD44 has been proposed
to be used for the isolation and enrichment of CSCs in
lung cancers including MPM [22, 24, 26, 100, 103].
That MPM contains a subpopulation of CSCs has been
reported by using putative CSC markers in addition to
CD44. For instance, the side population (SP) associated
with CD105 [104], SP, CD9, CD24 and CD26 [105] were
used in MPM cells lines and mesothelioma-derived
primary cells to identify the presence of a CSC subpop-
ulation. Using established CSC-associated genes, our
group detected the presence of polycomb ring finger
oncogene, (Bmi-1)+, urokinase plasminogen activator
receptor (uPAR)+ and ATP-binding cassette subfamily
G, member 2 (ABCG2)+ cells in 3 MPM cell lines, which
elicited resistance to cisplatin and pemetrexed, indicating
the presence of a drug- resistant CSC subpopulation
[106]. In the H28, H2052 and Meso4 MPM cell lines,
we noted a marked increase in CD44 transcript levels
within the putative CSC ALDH+CD44+-sorted cells after
cisplatin treatments, revealing the involvement of CD44 in
ensuing drug resistance [22]. Using an activated cell sorting
(FACS)-based assay, we also measured high percentages of
CD44+ cells in the following MPM cell lines: H28 – 48.5%;
H2052 - 57.6% and Meso4 – 50.2% relative to the entire
cell population sustaining the presence of a putative CSC
subpopulation (Cortes-Dericks et al., unpublished report).
There is reasonable consensus that CD44 as a putative
CSC marker could identify a drug-resistant subpopulation
[22, 24–26] – a possible clinical attribute of MPM, which
may be considered as a new diagnostic parameter of the
disease.
“Conventional” biomarkers in pleural effusion
and serum for MPM
Pleural fluid cytology is considered a reliable diagnostic
tool for MPM only in experienced centres. For this rea-
son, most of the patients undergo invasive procedures
such as core-needle biopsy or video-assisted thoracoscopy
to facilitate histological examination – the gold standard for
MPM diagnosis [5, 107–111]. Thus, the search for a nonin-
vasive diagnostic procedure that may confirm or exclude
the diagnosis of MPM is of major clinical interest [108].
Table 1 Diagnostic relevance of CD44 in MPM
Function Method/specimen Reference
High CD44 level indicates presence of neoplastic cells IHC/MPM tissues Penno et al. 1995 [79]
High CD44 level differentiates MPM from ADC IHC/reactive mesothelium, MPM, ADC samples Attanoos et al. 1997 [80]
CD44/HA localization discriminates MPM from ADC IHC/paraffin-embedded serous fluids Afify et al. 2005 [81]
CD44v6/CD44s ratio aids in differential diagnosis
between MPM and non-MPM tumors
ELISA/Pleural fluids Porcel et al. 2011 [84]
Low CD44 level aids in differential diagnosis of
pleural neoplastic differentiation
IHC/epitheloid MPM and reactive mesothelial
hyperplasia tissues
Ali et al. 2013 [82]
Low CD44 positivity and high HA staining may
differentiate MPM from ADC
IHC/MPM tissues Törronen et al. 2016 [83]
MPM malignant pleural mesothelioma, ADC adenocarcinoma, HA hyaluronic acid, IHC immunohistochemistry, ELISA enzyme-linked immunosorbent assay
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Biomarkers that can be analysed in serum, pleural effusions
or blood may solve the tedious diagnostic procedure. Those
that can be measured in pleural effusions have the advan-
tage of being readily applicable for analysis at the onset of
the first clinical symptoms for most patients [112] and may
allow the early detection of the disease.
The “conventional” biomarkers in pleural fluid and/or
serum for MPM still do not warrant an accurate diagnosis.
OPN, soluble mesothelin, formerly known as soluble
mesothelin-related peptide (SMRP) [113, 114], and mega-
karyocyte potentiating factor (MPF) also known as N-ECR/
mesothelin [112, 115] are supposed to be the most promis-
ing but with some limitations due to lack of specificity and
sensitivity [4, 116–118]. Mesothelin and MPF, both soluble
glycoproteins [119, 120] have sufficient specificity but have
a sub-optimal sensitivity for detection of MPM, being nega-
tive in both the sarcomatoid and almost half of the epithe-
loid subtype, particularly in the early stages [116, 121].
OPN lacks specificity for the diagnosis of MPM but may be
valuable in disease monitoring [116, 122].
The glycoprotein fibulin-3 is thought to have a high
diagnostic accuracy for MPM being able to distinguish
between asbestos-exposed non-MPM patients and early
stages of MPM [123]. However, Creany and associates
[124] found that although fibulin-3 is highly expressed
in MPM, its diagnostic power as a plasma or pleural effu-
sion biomarker is less than that of mesothelin. HA as a
single marker is not sufficient to discriminate MPM from
benign effusion [83]. Although increased levels of HA has
shown high diagnostic potential in MPM, its sensitivity
and specificity is low in detecting MPM [4, 125]. Other
tumor markers in serum and pleural fluid have been re-
ported to be of diagnostic importance such as cytokeratin-
19 fragment (CYFRA 21–1), carcinoembryonic antigen
(CEA), cancer antigen 15–3 (CA 15–3), cancer antigen
15–9 (CA 15–9) and tissue polypeptide antigen (TPA);
Table 2 Diagnostic value of HA in MPM
Function Method/specimen Reference
HA is associated with malignant tumor of the pleura Enzymatic analysis/pleural fluid Meyer and Chaffee. 1940 [85]
HA proposed as a diagnostic tool Electrophoresis/Pleural fluids Boersma et al. 1975 [91]
HA as a major GAG confirms MPM diagnosis Electrophoresis/MPM and other tumor tissues Waxler et al. 1979 [94]
High HA is a clinical finding in MPM GAG-degrading enzyme assay/pleural tissues Arai et al. 1979 [36]
Increased total GAG aids in differential diagnosis
between diffuse MPM and ADC
IHC/MPM tissues Kawai et al. 1985 [95]
HA indicates diffuse MPM Colorimetric assay/pleural fluids Matzel and Schubert. 1979 [93]
HA aids in differential diagnosis between MPM and
primary ADC
Electrophoresis/MPM and other tumor tissues Chiu et al. 1984 [87]
Increased HA level is associated with tumor damage IHC/pleural effusions Thylen et al. 1999 [88]
Dahl et al. 1989 [35]
HA is an indicator for MPM HPLC/pleural and peritoneal effusions Roboz et al. 1985 [86]
Increased serum HA indicates progressive MPM Radiometric assay/patient serum Frebourg et al. 1987 [34]
Dahl et al. 1984
Thylen et al. 1994
HA and chondroitin sulfate are basic features of MPM IHC/tumor tissues and pleural fluids Nakano et al. 1986 [96]
Positive HA staining highly predictive of MPM HA-binding probe/MPM and ADC tissues Azumi et al. 1992 [90]
Presence of HA distinguishes MPM from ADC IHC, HPLC/pleural effusion and tumor tissues Klominek et al. 1989 [89]
Attanoos et al. 1997 [80]
High HA with CEA aid in differential diagnosis of MPM Radiometric assay/Pleural fluids and patient serum Atagi et al. 1997 [92]
Pettersson et al. 1988 [33]
Increased HA-binding in pleural effusion cells serves
as additional diagnostic marker
[3H] hyaluronate binding assay/primary cell cultures Teder et al. 1996 [99]
High intracellular HA delineates MPM from ADC IHC/serous fluids Afify et al. 2005 [81]
Increased HA level is not specific for MPM diagnosis ELISA assay/Pleural effusions and serum Hillerdal et al. 1991 [98]
Combination of HA and cytology may improve diagnosis
of MPM
Immunoassay and IHC/pleural effusions Welker et al. 2007 [97]
HA >100 000 ng/ml recommended as diagnostic indicator
for MPM
ELISA assay pleural fluids of MPM and other tumors Fujimoto et al. 2013 [31]
High HA is associated with MPM IHC/MPM tissues Töronnen et al. 2016 [83]
MPM malignant pleural mesothelioma, ADC adenocarcinoma, HA hyaluronic acid, GAG glycosaminoglycan, IHC immunohistochemistry, ELISA enzyme-linked
immunosorbent assay, HPLC high pressure liquid chromatography
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however, these markers are not sensitive or specific
enough and, thus, cannot be applied clinically [4].
At this time, mesothelin remains the most clinically
useful and the only Food Drug and Administration
(FDA)-approved, single-best blood-based biomarker in
the diagnosis of MPM. It has also been proposed to be
a standard control in testing the sensitivity of a potential
biomarker [117, 122, 124, 126–129].
“Best practice” biomarker, mesothelin combined
with other potential markers
Owing to the restrictions in sensitivity and specificity of
single biomarkers, the use of combinatorial biomarkers
have been evaluated to discriminate between asymptomatic
asbestos-exposed subjects and early-stage MPM patients.
As mesothelin is considered the most useful biomarker in
MPM [117, 124, 126], a number of studies have been
undertaken to enhance its diagnostic competence.
The combination of CA125 and serum mesothelin were
evaluated in patients with MPM, healthy asbestos-exposed
individuals, patients with asbestos-related lung disease and
with benign pleural effusions to augment the sensitivity of
mesothelin as a single marker. The results from this study
did not show improvement of the combined CA125 and
mesothelin relative to the sensitivity of mesothelin alone
[130]. Notably, combined mesothelin and CEA enhanced
the diagnostic accuracy in distinguishing MPM from
non-small cell lung cancer (NSCLC) [131]. Muley and
coworkers [132] also obtained data attesting that the
dual application of mesothelin and CEA significantly
increased the differential diagnosis between MPM and
other lung cancers, and also between MPM and benign
asbestos disease. Hence, these authors endorsed the
combination of both markers for the diagnosis as well
as for differential diagnosis.
The combination of serum mesothelin and HA has
not improved the diagnostic performance over mesothelin
alone [129]. Adversely, the team of Creany [125] furnished
information that the combination of the “best practice”
biomarker, mesothelin and HA have a higher diagnostic
capability than using effusion mesothelin as a single
marker. A comparative study between the diagnostic
accuracy of fibulin-3 and mesothelin in the plasma and
pleural effusions of MPM patients indicated that mesothelin
generates a better diagnostic efficiency compared with
fibulin-3 for MPM, whereas fibulin-3 renders superior
prognostic values relative to mesothelin [124].
The combined diagnostic power of OPN and mesothelin
did not provide a stronger diagnostic capacity than that of
mesothelin alone [133]. Even the combination of OPN,
MPF and mesothelin did not furnish a superior effect than
mesothelin alone. Intriguingly, a recent study reported
that the combination of serum OPN and mesothelin
have a diagnostic potential in differentiating MPM from
benign asbestos-related diseases and asbestos-exposed
subjects [134].
At the clinical setting, studies on the combination of
biomarkers have not been diagnostically satisfactory over
individual markers but is encouraging as sensitive, soluble
markers are emerging and being tested [9, 116, 118].
CD44 and HA as potential biomarkers in MPM
The review of literature presented herein strongly im-
plies that CD44 and its ligand HA are potentially useful
biomarkers in MPM. The increased expression levels of
both molecules in MPM tissues and pleural fluids as
compared with the normal mesothelial cells strongly re-
inforces their implication in the development of MPM
as well as their diagnostic performance. A tight CD44/
HA interaction also asserts that both molecules convey
biological actions in a concerted manner so that both
may be considered as tandem biomarkers. CD44/HA as
dual markers have been suggested in the differential
diagnosis between MPM and ADC. As these markers
still do not provide diagnostic accuracy, the inclusion of
both CD44 and HA in a panel of biomarkers has been
recommended [83]. As mentioned earlier, the combin-
ation of mesothelin/HA has shown an improved diagnos-
tic accuracy. In this context, the incorporation of CD44 in
the combined mesothelin/HA may even generate a reli-
able diagnosis, which warrants an extensive validation.
The proposed criteria for future biomarkers for MPM
namely; their measurability in biological samples using
minimally invasive tests, to differentiate MPM from benign
pleural disease, applicability for all pathological subtypes
and correlation with the extent of malignancy [4, 135], may
be well achieved after appropriate in vitro and clinical
evaluation. HA, CD44s and CD44 isoforms can readily
be detected by an ELISA (enzyme-linked immunosorbent
assay) assay in pleural effusion, serum, plasma and other
biological fluids, which can be procured in a noninvasive
procedure. Several MPM putative biomarkers have been
generally based on the expression levels of molecules via
mRNA microarray studies [118, 136–138], which can also
be used for measuring the expression levels of CD44 and
its isoforms including HA. Apart from the potential of
CD44 and HA to provide an accurate diagnosis, the prac-
ticability of evaluating the expression levels also warrants
faster results and less exhausting method for the patient.
Conclusion
The general recommendations from the different patholo-
gists worldwide for the diagnosis of MPM still advocate the
use of an immunohistological examination of a convention-
ally stained tissue samples as the gold standard for MPM
diagnosis [5, 118, 139, 140]. It still takes several months
between the first signs of the disease and a definite
diagnosis of MPM is achieved. Rationally, there should
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be a marker or a combination of markers that will offer an
accurate diagnosis of MPM based on pleural effusion ana-
lysis that may be incorporated with routine immunohisto-
chemistry or electron microscopy of cell pellets [112].
There is ample evidence that one marker alone is not suf-
ficient to detect, differentiate and specifically diagnose
MPM. Because of the tight association of HA and CD44,
it stands to reason that combining the two markers or
their inclusion in a panel of markers may serve as adju-
vant diagnostic tool to efficiently aid the early and most
likely specific diagnosis of MPM.
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